Mohamed E. Salem, MD, a medical oncologist at Levine Cancer Institute, Atrium Health, discusses the results of the MyPathway trial in metastatic colorectal cancer (mCRC).

In terms of HER2, a lot of what is known in breast cancer is applicable in mCRC, explains Salem. In that space, physicians learned about HER2 as a physiology and how to target it. Through advances made in technology and the ability of next-generation sequencing, it was discovered that approximately 3% to 5% of patients have 

 overexpression. Now, there are drugs that can target 

-amplified tumors. For example, data from the HERACLES trial demonstrated the activity of anti-HER2 therapy in the refractory setting.

More recently, data from the MyPathway trial published in 

showed the activity of anti-HER2 therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) in patients with 

-amplified tumors in the refractory setting. The objective response rate was about 32%. Moreover, 2% of patients achieved a complete response, and the disease control rate was about 40%. Although the sample size was small, there was a signal of activity that has to be weighed against historical response rates of 1%. The data also suggest a relationship between resistance to anti-EGFR therapy and 

Videos

Dr. Salem on the Results of the MyPathway Trial in mCRC

Metastatic colorectal cancer (mCRC) has been transformed from a one-drug disease with a median overall survival (mOS) rate of 6 months to one that presents an opportunity for multiagent, multimodality treatment pathways with an overall survival (OS) rate of nearly 3 years. This progress can be attributed to a continually growing understanding of the variable molecular biology of CRCs; the vast improvement in technology offering a way to assess these differences and, to some degree, tailor treatment to them (eg, for EGFR and HER2 inhibition); and increased access to novel, more diverse, and selective therapies.

Currently, the standard first-line treatment for inoperable mCRC is combination chemotherapy with an oxaliplatin- or irinotecan-based fluoropyrimidine- containing regimen (usually FOLFOX, FOLFIRI or FOLFOXIRI), commonly combined with a biological agent—ordinarily either the anti-VEGF inhibitor bevacizumab, or, for patients with 

 wild-type tumors only, the anti-EGFR inhibitors, cetuximab or panitumumab. Until recently, bevacizumab and cetuximab seemed to have the same efficacy when added to chemotherapy in the frontline treatment of 

A myriad of data supports the standard practice described above. However, in light of a new retrospective analysis, carried out by Venook and colleagues, this tradition is now being challenged. The potentially practice-changing post factum analysis of the Cancer and Leukemia Group B/ Southwest Oncology Group (CALGB/SWOG 80405) trial, recounted by Alan P. Venook, MD, at the 2016 ASCO Annual Meeting, demonstrated that in patients with mCRC receiving first-line therapy, the anatomic location of the tumor within the colon appears to have an impact not only on patient survival 

 but also on response to biological therapy. The apparent efficacy of bevacizumab and cetuximab differs according to the location of the patient’s tumor (whether in the right or left side of the colon).

Thus, patients with tumors originating in the right side of their colon generally had a much shorter mOS (19.4 months) than patients whose tumors seeded in the left side (33.3 months; HR, 1.60; 

 wild-type and mutant tumors, regardless of cetuximab or bevacizumab-containing therapy 

Furthermore, among patients who received cetuximab, mOS was 16.7 months for those with right-sided primary tumors, compared with 36 months for those who had left-sided primaries. Similarly, patients receiving bevacizumab had an mOS of 24.2 months versus 31.4 months, depending on whether their primary was right or left-sided, respectively.

These results suggest that cetuximab might actually be detrimental to patients with right-sided tumors, making bevacizumab the better option for these patients, regardless of 

 status. On the other hand, it seems that cetuximab was better for left-sided tumors 

As a disconcerting side note, patients with primary tumors that were right-sided RAS-mutated appeared to have a better response to cetuximab than those that were right-sided RAS wild-type (23.3 vs 16.7 months). If this finding is further validated, it throws our whole belief system into question, or in Venook’s words, “if true, we know less about RAS than we think we do”.

Venook concluded that all differences in his reported study are probably due to differences in the underlying biology and that the anatomic location is a perhaps a proxy of these biological differences.

In a recent study published in JAMA, Tejpar and colleagues reported on a retrospective analysis investigating the prognostic and predictive value of primary tumor location in patients with RAS wild-type mCRC who took part in the CRYSTAL and FIRE-3 trials.2 Patients with left-sided (splenic flexure, descending colon, sigmoid colon, or rectum) or right-sided (appendix, cecum, ascending colon, hepatic flexure, or transverse colon) mCRC were assessed for their progression-free survival (PFS) and OS according to their treatment arm. The authors concluded that patients with RAS wild-type left-sided tumors had markedly superior PFS, OS, and overall response rate (ORR) compared with patients with right-sided tumors. Furthermore, FOLFIRI plus cetuximab benefited patients with left-sided RAS wild-type tumors much more significantly than did FOLFIRI alone or FOLFIRI plus bevacizumab, whereas patients with right-sided tumors derived limited benefit.

Although these investigations are innovative, we have to keep in mind that these findings are a product of a retrospective unplanned analysis—a caveat that Venook himself highlighted. It seems reasonable that physicians should perhaps not use cetuximab in the treatment of patients with right-sided tumors due to the probability of inferior outcomes.

However, whether to use bevacizumab or cetuximab in the first-line treatment of patients with left-sided tumors is still a matter of debate, and the answer to this question lies in the design and execution of well-planned, prospective, randomized trials in patients with validated left- or right-sided CRCs receiving standard chemotherapy plus VEGF or EGFR inhibitors. For now, the decision to use cetuximab over bevacizumab for KRAS wild-type left-sided tumors remains a personal one for the patient and physician.

Another study based on an analysis of the SEER database, presented by Deborah Schrag, MD, MPH, at the 2016 ASCO Annual Meeting, revealed that patients with right-sided stage III or IV CRC had inferior mOS compared with left-sided colon and rectal tumors.

A third study, presented by Michael Sangmin Lee, MD, profiled 198 

 wild-type mCRC tumors and found that right-sided tumors were associated with CpG island methylator phenotype (CIMP)-high status (ORR, 2.35, 95% CI 1.22-4.54) and higher BRAF mutation rates (ORR, 5.45, 95% CI 2.47-12.03), conferring worse patient survival outcomes and an inferior response to anti-EGFR therapies.

Such tumor location—dependent differences in patient outcome are likely due to differences in biology between the right and left sides of the colon, somehow affecting response to therapy. These findings likely are not surprising in light of the recent consensus regarding the molecular subtyping of CRC, wherein it was classified into 4 different groups: CMS1 (microsatellite instability immune), CM2 (canonical), CMS3 (metabolic), and CMS4 (mesenchymal).

 Differential distribution of the 4 classes in various anatomic localities suggests biological differences between colorectal tumors within these different regions.

Before sidedness became an acknowledged consideration in the treatment of CRC, several studies compared cetuximab with bevacizumab chemotherapy regimens in the treatment of this disease. The multicenter FIRE-3 trial compared FOLFIRI plus cetuximab with FOLFIRI plus bevacizumab in the first-line treatment of 592 patients with KRAS exon 2 wild-type mCRC.

The study found no significant differences in median progression-free survival (mPFS) between the 2 arms (10.0 months in the cetuximab arm vs 10.3 months in the bevacizumab arm, P = .55), although mOS was significantly longer in the cetuximab arm (28.7 vs 25.0 months; 

Likewise, in an extended RAS wild-type population, mPFS was similar (10.4 months in the cetuximab arm vs 10.2 months in the bevacizumab arm; 

= .54), but mOS was markedly longer in the cetuximab arm (33.1 vs 25.6 months; 

 In his 2016 ASCO presentation, Venook incorporated results from a recent retrospective left- versus rightsided analysis of patients in the FIRE-3 trial that the authors had shared with him. Results from the FIRE-3 trial corroborated with those from the CALGB/SWOG 80405 trial: the OS of patients with left-sided tumors was more than double that of individuals with right-sided tumors.

In the original CALGB/SWOG 80405 phase III trial, conducted between November 2005 and March 2012, the initial plan was to enroll patients unselected for their KRAS status. However, after 4 years of research, the inclusion criteria were altered to allow only patients with 

 wild-type tumors into the study. Of 2334 patients with 

 wild-type tumors (exon 2, codons 12 and 13) randomly assigned to receive chemotherapy plus cetuximab or chemotherapy plus bevacizumab (regardless of primary tumor side), the mOS was found to be equivalent in the 2 treatment arms: 29.9 months (range, 27.6-31.2 months) in the cetuximab group versus 29.0 months (range, 25.7-31.2 months) in the bevacizumab group.9 These findings demonstrated that if mCRC is taken as one disease, regardless of primary location, both bevacizumab and cetuximab are appropriate choices for addition to a chemotherapeutic backbone when treating patients with 

However, the discovery that CRC has multiple biological “personalities” depending on the primary tumor site has caused oncologists to question the concept of one-biologic-fits-all sites.

Venook’s recently presented data have opened the door to many interrelated questions, such as whether sidedness of the primary tumor has an impact on the benefit of biologics in the adjuvant setting.

Both bevacizumab and cetuximab were previously tested in the adjuvant setting but with no promising outcome. However, now we can wonder whether tumor sidedness has an impact on outcome, and whether we should reanalyze data for this variable. Other questions relate to standard chemotherapy as a backbone of treatment: could sidedness affect response to different cytotoxic chemotherapy regimens?

It is noteworthy that results from the retrospective analyses of the CALGB/SWOG 80405,1 CRYSTAL, and FIRE-3 trials2 were based on differences between tumors in the right or left colon, where left-sided tumors were defined as splenic flexure, descending colon, sigmoid colon, and rectal tumors. However, do all left-sided tumors share the same molecular features, particularly those in the colon versus the rectum? That is, are rectal tumors clinically and biologically different from colon tumors, and do these differences impact response to therapy? Indeed, we are currently examining the molecular and clinical variances between rectal and left-sided colon cancers.

On this note, our group is collaborating with others to study the use of molecular profiling to design a targeted-agent approach to the treatment of mCRC. In one such collaborative study of molecularly tailored first-line chemotherapy in patients with mCRC (SMarT Choice Study), we are trying to personalize the first-line treatment of mCRC by employing a full panel of molecular biomarkers and a treatment algorithm that provides a guide for treatment selection for each patient.

In this study, we will test the feasibility and effectiveness of applying a real-time panel of biomarkers (

) to guide the selection of first-line treatment in patients with chemotherapy-naïve mCRC, aiming to develop a strategy that will provide each patient with a personalized treatment recommendation.

For decades, it was assumed that CRC was one disease. However, researchers are now beginning to understand that it is a heterogeneous and biologically diverse cancer. Moreover, it is becoming evident that oncologists should not simply treat all patients with CRC with the same regimen. Personalized treatment plans must be developed for each patient based on their tumor’s genetic subtype and, perhaps, location.

It is highly probable that molecular profiling is the key to more precise treatments, as well as prediction of outcomes. In this fascinating new era of oncology, we are beginning to look for ways to minimize treatment and best determine how to customize therapy for each individual patient.

More data are certainly needed, and further prospective studies are required to confirm such findings, but it is becoming unmistakable now that a one-biologic-fits-all sites approach does not apply to CRC, which is certainly no longer a one-size-fits-all disease.

 We would like to thank Marion L. Hartley, PhD, science writer for clinical research at the Ruesch Center for the Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center, Georgetown University, for her edits and suggestions during the composition of this article.

Venook AP, Niedzwiecki D, Innocenti F, et al. Impact of primary (1º) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance). J Clin Oncol. 2016;34(suppl; abstr 3504).

Schrag D, Weng S, Brooks G, et al. The relationship between primary tumor sidedness and prognosis in colorectal cancer. J Clin Oncol. 2016;34(suppl, abstr 3505).

Lee MS, Advani SM, Morris J, et al. Association of primary (1°) site and molecular features with progression-free survival (PFS) and overall survival (OS) of metastatic colorectal cancer (mCRC) after anti-epidermal growth factor receptor (αEGFR) therapy. J Clin Oncol. 2016;34(suppl; abstr 3506).

Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21(11): 1350-1356. doi: 10.1038/nm.3967.

Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360(14):1408-1417. doi: 10.1056/NEJMoa0805019.

Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(10):1065-1075. doi: 10.1016/S1470-2045(14)70330-4.

Venook AP, Niedzwiecki D, Lenz H-J, et al. CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J Clin Oncol. 2014;32:5s(suppl: abstr LBA3).

Articles

It is highly probable that molecular profiling is the key to more precise treatments, as well as prediction of outcomes in metastatic colorectal cancer.

Mohamed E. Salem, MD

Articles

Dr. Salem on the Results of the MyPathway Trial in mCRC

Tumor Location Insights in mCRC Challenge Standard of Care